Science Group PLC trading update: cash-rich and edging ahead of plan
Science Group PLC has delivered a steady nine-month trading update to 30 September 2025. The headline: performance is broadly as anticipated, the recovery in R&D services is taking hold in the Medical sector, and full-year Adjusted Operating Profit (AOP) is set to land in line or slightly ahead of the Board’s expectations.
Add in a sizeable exceptional pre-tax gain of £24.0 million from the H1 strategic investment and a chunky cash position, and this is a business with firepower. The tone is measured, but the numbers are quietly confident.
Key numbers from the nine-month period
| Metric | Figure | Notes |
|---|---|---|
| Gross cash (30 Sep 2025) | £77.6 million | After dividend and tax instalment payments |
| Net funds (30 Sep 2025) | £66.0 million | Cash minus borrowings |
| Dividend paid (July 2025) | £3.6 million | Cash outflow to shareholders |
| Tax paid on H1 gain (first instalment) | £2.5 million | Further instalments likely, timing not disclosed |
| Share buy-backs (year to date) | £4.4 million | Ongoing capital returns |
| Exceptional pre-tax gain (H1) | £24.0 million | From strategic investment; one-off |
| FY2025 AOP outlook | In line or slightly ahead | No numeric guidance disclosed |
Adjusted Operating Profit explained – and why guidance matters
AOP stands for Adjusted Operating Profit – operating profit excluding certain one-off or non-cash items, used by many companies to show underlying performance. Science Group reported another period of record AOP at the interim results on 28 July 2025, despite a choppy market backdrop.
Today’s update says full-year AOP should be in line or a touch ahead of the Board’s expectations. The company has not disclosed the exact expectation, but holding or nudging guidance up in volatile conditions is a positive signal about visibility and order intake.
Big cash balance, healthy net funds: optionality secured
At 30 September 2025, gross cash stood at £77.6 million with net funds of £66.0 million. Net funds simply means total cash minus any debt; a positive figure indicates more cash than borrowing.
This balance sheet strength gives Science Group room to manoeuvre – whether that is investing in growth, continuing buy-backs, or weathering any short-term swings in client demand. The update specifically notes the cash inflow associated with the £24.0 million strategic investment gain in H1, which clearly helps.
Capital allocation: dividends, buy-backs and the £24.0 million gain
Shareholders have seen tangible returns year to date. The company paid a £3.6 million dividend in July and has repurchased £4.4 million of shares so far in 2025. Those buy-backs can enhance per-share metrics when done at sensible prices.
On top, the H1 strategic investment delivered a substantial exceptional pre-tax gain of £24.0 million and associated cash inflow. That is a one-off, not part of ongoing trading, but it strengthens the financial position. The first tax instalment of £2.5 million on that gain has been paid – further tax timing and amounts are not disclosed.
Sector trends: Medical-led recovery within R&D services
Management flags that business confidence remains subdued in some sectors, which chimes with broader macro uncertainty. However, in aggregate, performance is as anticipated, and importantly the recovery in R&D services – driven by the Medical sector – is progressing as expected.
That balance matters. Science Group’s diversified exposure means weakness in some areas can be offset by strength elsewhere. The Medical-driven rebound provides a stabiliser for group-level results, at least for now.
Outlook for FY2025: steady and slightly improving
The company reiterates it is on track to deliver another strong performance for the year ending 31 December 2025. The phrasing “in line or slightly ahead of the Board’s expectations” for AOP is modestly encouraging given the “volatile market conditions” acknowledged in the statement.
There is no quantitative guidance or order book detail in this update. The next catalysts are not disclosed, but investors will naturally look for confirmation of the R&D services recovery, visibility into any further tax payments on the H1 gain, and ongoing capital return activity.
Positives, watch-outs and what it means for investors
- Positives: strong net funds of £66.0 million; ongoing R&D recovery in Medical; disciplined capital returns with £3.6 million dividend and £4.4 million buy-backs; AOP set to meet or slightly beat expectations.
- Watch-outs: management notes subdued confidence in some sectors; exceptional gains are one-off by nature; tax on the H1 gain will reduce cash over time, with only the first £2.5 million instalment disclosed.
- Why it matters: a cash-rich, services-led group with improving end-market dynamics can fund growth and shareholder returns without over-relying on debt – a valuable position if volatility persists.
Josh’s view: financially fit, sensibly paced
This reads like a controlled, well-managed update. Science Group is not swinging for the fences, but it does not need to. Record AOP at the half-year, a robust cash position at £77.6 million, and clear capital returns put the company in a strong spot to navigate mixed market sentiment.
The absence of hard numbers for AOP expectations leaves some room for interpretation, but “in line or slightly ahead” is the right kind of phrasing this late in the year. The Medical-led R&D recovery is the operative trend to monitor. Overall, a solid, shareholder-friendly trajectory with the balance sheet to back it up.
Company site: www.sciencegroup.com
